Want to see HK:2291 full AI Analyst Report?
Top Page
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
(2291)
Select Model
Select Model
Rating:85Outperform
Price Target:
HK$17.00
▲(25.28% Upside)
Action:Reiterated
Date:08/22/26
The score is driven primarily by strong financial quality (high margins and an exceptionally low-leverage balance sheet), supported by a bullish technical trend with moderate momentum. Valuation is fair-to-attractive due to a reasonable P/E and solid dividend yield, partially offset by the 2025 revenue decline and the business’s historical earnings/cash-flow volatility.
Positive Factors
High profitability
Very high gross and operating margins, including a 2025 net margin of about 46%, indicate strong earnings power. This profitability can support product investment and resilience, although historical volatility remains a consideration.
Negative Factors
2025 revenue contraction
The 2025 revenue decline indicates that prior expansion has slowed and may reflect weaker demand, product-cycle effects, or execution pressure. Sustained contraction would limit operating leverage and make future profit growth less dependable.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability
Very high gross and operating margins, including a 2025 net margin of about 46%, indicate strong earnings power. This profitability can support product investment and resilience, although historical volatility remains a consideration.
Read all positive factors
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H (2291) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.58B
Dividend Yield4.65%
Average Volume (3M)1.30M
Price to Earnings (P/E)19.3
Beta (1Y)0.93
Revenue Growth-4.20%
EPS Growth-25.69%
CountryHK
Employees371
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.69
Shares Outstanding344,694,000
10 Day Avg. Volume916,200
30 Day Avg. Volume1,298,539
Financial Highlights & Ratios
PEG Ratio-7.43
Price to Book (P/B)2.46
Price to Sales (P/S)9.49
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.03
Revenue Forecast (FY)HK$751.00M
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of s...
How the Company Makes Money
null...
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
94
Very Positive
Cash Flow
78
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 527.94M | 471.64M | 325.90M | 247.67M | 222.58M |
| Gross Profit | 446.95M | 424.03M | 288.81M | 219.69M | 197.54M |
| EBITDA | 292.60M | 288.10M | 189.20M | 18.81M | 87.38M |
| Net Income | 239.73M | 245.56M | 151.53M | -19.81M | 58.70M |
Balance Sheet | |||||
| Total Assets | 2.10B | 2.08B | 1.99B | 1.81B | 1.12B |
| Cash, Cash Equivalents and Short-Term Investments | 1.16B | 1.13B | 1.27B | 1.20B | 713.48M |
| Total Debt | 1.72M | 1.51M | 2.44M | 3.33M | 6.19M |
| Total Liabilities | 61.47M | 85.98M | 59.79M | 65.09M | 734.50M |
| Stockholders Equity | 2.04B | 2.00B | 1.93B | 1.74B | 385.19M |
Cash Flow | |||||
| Free Cash Flow | 144.66M | 137.05M | 66.75M | -17.83M | 13.44M |
| Operating Cash Flow | 221.10M | 222.49M | 164.26M | 65.53M | 105.28M |
| Investing Cash Flow | 28.73M | -117.22M | 111.32M | -406.00M | -85.17M |
| Financing Cash Flow | -216.55M | -196.91M | -2.05M | 577.80M | 672.23M |
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | HK$4.58B | 19.29 | 10.01% | 4.65% | -4.20% | -25.69% | |
61 Neutral | HK$1.16B | 2.49 | 16.37% | 15.64% | 7.27% | 8.34% | |
60 Neutral | HK$408.58M | 130.39 | 2.93% | 36.59% | -2.70% | -64.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$809.55M | 18.58 | 8.99% | 3.06% | 13.24% | -42.14% | |
48 Neutral | HK$765.00M | -39.23 | -56.60% | 12.05% | 46.69% | -24.56% | |
43 Neutral | HK$341.12M | -3.41 | 324.17% | ― | -13.98% | 47.47% |
* Healthcare Sector Average
HK:2291
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
12.31
-8.88
-41.91%
HK:9616
Neusoft Education Technology Co. Limited
1.79
-0.60
-25.25%
HK:1586
China Leon Inspection Holding Limited
1.40
-1.40
-50.18%
HK:1631
REF Holdings Limited
1.32
0.82
164.00%
HK:8391
Cornerstone Technologies Holdings Limited
0.30
-0.32
-51.61%
HK:8450
EDICO Holdings Limited
0.80
0.68
545.16%
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Corporate Events
Lepu ScienTech Plans RMB1.09 Billion Connected Acquisition in Biotech Arm
Aug 21, 2026
Lepu ScienTech Medical Technology (Shanghai) Co., Ltd., a Hong Kong-listed PRC medical technology group, is expanding its footprint in biotechnology through a large related-party investment. The company’s governance framework requires that m...
Lepu ScienTech Profit Slides as Cardiovascular Device Maker Tightens Spending
Aug 21, 2026
Lepu ScienTech reported that for the six months ended 30 June 2026, revenue fell 5.9% year-on-year to RMB310.1 million and gross profit dropped 10.5% to RMB254.5 million, while net profit attributable to shareholders declined 19.5% to RMB146.5 mil...
LEPU ScienTech Schedules Board Meeting to Review Interim Results and Dividend
Aug 11, 2026
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. has scheduled a board meeting for August 21, 2026 to review and approve the interim results for the six months ended June 30, 2026, along with their planned publication. The board will also co...
LEPU ScienTech Shareholders Approve All AGM Resolutions and Capital Mandates
May 22, 2026
Shareholders of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. overwhelmingly approved all resolutions at the 2025 annual general meeting held in Shanghai on May 22, 2026. Routine matters including the 2025 work reports of the Board and Bo...
LEPU ScienTech Updates Final Dividend Details and Tax Arrangements
May 22, 2026
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. has declared a final ordinary dividend of RMB 0.5 per share for the financial year ended 31 December 2025, with shareholder approval obtained on 22 May 2026. The dividend for H-share investors...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.